Drug Development

Articles

Pall has agreed to be acquired by Danaher for $127.20 per share.

Pall to be Acquired by Danaher

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

Baxter BioScience Expands Oncology Business

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.

FDA Releases Q&A on Biosimilars

A vaccine patch may eliminate the need for traditional means of vaccine distribution, according to an article in NPR.

Vaccine Patch Could Eliminate Traditional Protocol for Vaccine Delivery

The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.

Court Blocks First FDA-Approved Biosimilar, for the Time Being

Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.

Biosimilar Giants Launch Biosimilars Forum

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Advances in transdermal drug delivery, particularly with microneedles, are enabling a wider range of drugs to be delivered through the skin.

Transdermal Drug Delivery Gains Traction

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Intellectual property lawyers estimate biosimilar litigation will swell as early as 2018.

Biosimilars Will Bring Significant Litigation and Patent Challenges

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

Biomanufacturing Outsourcing Globalization Continues

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

An integrated pilot plant tests heteronucleation and continuous crystallization.

Formulation and Drug Delivery